Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07821112 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile®

Name: Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile® — clinical trial record (NCT07821112)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ENDURANCE

StatusNot Yet Recruiting

PhasePhase 2

SponsorUniversity of California, Irvine

Started2026-10

View on ClinicalTrials.gov ↗

This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.

Trial Details

NCT Number	NCT07821112
Lead Sponsor	University of California, Irvine Collaborators: GT Medical Technologies, Inc.
Conditions	Glioma, Glioblastoma, GBM, Glioma, Malignant, Astrocytoma, Oligodendroglioma, Elderly Glioblastoma, Elderly GBM
Enrollment	20 participants
Start Date	2026-10
Primary Completion	2027-10 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2026-09-15